Repair effect of poly(lactic-co-glycolic acid) nanospheres with sustained-release of neurotrophin-3 and ganglioside GD1a on spinal cord injury in rats

doi:10.12307/2023.168

Abstract

Abstract: BACKGROUND: Non-invasive treatment of spinal cord injury needs to be developed urgently. Nanomaterials have obvious advantages, which can deliver drugs and improve the therapeutic effect.
OBJECTIVE: To fabricate sustained-release nanospheres containing neurotrophin-3 and ganglioside GD1a by poly(lactic-co-glycolic acid) and investigate their effects on the repair of spinal cord injury in rats.
METHODS: Poly(lactic-co-glycolic acid) nanospheres encapsulated with neurotrophin-3 and ganglioside GD1a were prepared using oil-water emulsion volatile organic solvent method. The sustained release properties of microspheres were tested. Sixty female adult SD rats were randomly divided into five groups with 12 rats in each group. In the sham operation group, the lamina was opened and sutured directly. In the spinal cord injury group, a spinal cord T9 impingement injury model was established. In the neurotrophin group, the nanosphere suspension of slow-release neurotrophin-3 was injected into the injured area of spinal cord T9. In the ganglioside GD1a group, the sustained-release ganglioside GD1a nanosphere suspension was injected into the spinal cord T9 injury area. The experimental group was injected with nanosphere suspension of sustained-release neurotrophin-3 and ganglioside GD1a in the injured area of spinal cord T9. Open field test and BBB scoring were conducted weekly after operation. The sections were taken 4 and 8 weeks after surgery for morphological observation.
RESULTS AND CONCLUSION: (1) After soaking in PBS for 14 days in vitro, the sustained-release nanospheres could continuously release neurotrophin-3 and ganglioside GD1a. (2) At 7 and 8 weeks after surgery, compared with the spinal cord injury group, the BBB score and the total open field distance of the rats increased in the neurotrophin group and the experimental group (P < 0.05). The results of Nissl staining showed that at 4 and 8 weeks after surgery, the number of motor neurons increased in the anterior horn of caudal gray matter in the experimental group compared with the spinal cord injury group (P < 0.05). At 8 weeks after surgery, the number of motor neurons increased in the anterior horn of caudal gray matter in the neurotrophin group compared with the spinal cord injury group (P < 0.05). The results of immunofluorescence staining showed that compared with the spinal cord injury group, the neurotrophin group at 8 weeks and the experimental group at 4 and 8 weeks had increased spinal white matter ventral nerve fibers (P < 0.05); the expression of myelin basic protein on the ventral side of the spinal cord white matter increased at 4 and 8 weeks in the ganglioside GD1a and experimental groups (P < 0.05); the expression of myelin basic protein in the neurotrophin group increased at 8 weeks after operation (P < 0.05); the descending propriospinal tract increased in the neurotrophin group and the experimental group at 8 weeks (P < 0.05). (3) The results showed that neurotrophin-3 microspheres alone or in combination with ganglioside GD1a microspheres could promote the survival of motor neurons and nerve fibers around the spinal cord injury site and improve the motor function of the hind limbs of rats.

Key words: spinal cord injury, neurotrophin-3, gangliosides, poly(lactic-co-glycolic acid), tissue engineering, nerve regeneration

CLC Number:

Xia Yu, Sun Jia, Qi Zhengyan, Ma Lin, Ma Wenqian, Niu Jianguo, Wen Yujun. Repair effect of poly(lactic-co-glycolic acid) nanospheres with sustained-release of neurotrophin-3 and ganglioside GD1a on spinal cord injury in rats[J]. Chinese Journal of Tissue Engineering Research, 2023, 27(16): 2518-2524.

Figures/Tables 6

References

[1] GUO S, REDENSKI I, LANDAU S, et al. Prevascularized Scaffolds Bearing Human Dental Pulp Stem Cells for Treating Complete Spinal Cord Injury. Adv Healthc Mater. 2020;9(20):e2000974.
[2] SHI B, DING J, LIU Y, et al. ERK1/2 pathway-mediated differentiation of IGF-1-transfected spinal cord-derived neural stem cells into oligodendrocytes. PloS One. 2014;9(8):e106038.
[3] YANG B, ZHANG F, CHENG F, et al. Strategies and prospects of effective neural circuits reconstruction after spinal cord injury. Cell Death Dis. 2020;11(6):439.
[4] GU Y, ZHANG R, JIANG B, et al. Repair of Spinal Cord Injury by Inhibition of PLK4 Expression Through Local Delivery of siRNA-Loaded Nanoparticles. J Mol Neurosci. 2021;72(3):544-554.
[5] BADHIWALA JH, AHUJA CS, FEHLINGS MG. Time is spine: a review of translational advances in spinal cord injury. J Neurosurg Spine. 2019; 30(1):1-18.
[6] YE J, XUE R, JI ZY, et al. Effect of NT-3 on repair of spinal cord injury through the MAPK signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24(5):2165-2172.
[7] MUHEREMU A, SHU L, LIANG J, et al. Sustained delivery of neurotrophic factors to treat spinal cord injury. Transl Neurosci. 2021;12(1):494-511.
[8] HAN Q, XU X. Neurotrophin-3-mediated locomotor recovery: a novel therapeutic strategy targeting lumbar neural circuitry after spinal cord injury. Neural Regen Res. 2020;15(12):2241-2242.
[9] XU Z, ZHANG L, ZHOU Y, et al. Histological and functional outcomes in a rat model of hemisected spinal cord with sustained VEGF/NT-3 release from tissue-engineered grafts. Artif Cells Nanomed Biotechnol. 2020;48(1):362-376.
[10] CHINNOCK P, ROBERTS I. Gangliosides for acute spinal cord injury. Cochrane Database Syst Rev. 2005;2005(2):CD004444.
[11] HE Y, LI J. Ganglioside GD1a inhibits LPS-induced inflammation in types of cells. Int Immunopharmacol. 2016;31:222.
[12] AZZAZ F, YAHI N, DI SCALA C, et al. Ganglioside binding domains in proteins: Physiological and pathological mechanisms. Adv Protein Chem Struct Biol. 2022;128:289-324.
[13] QIN J, SIKKEMA AH, VAN DER BIJ K, et al. GD1a Overcomes Inhibition of Myelination by Fibronectin via Activation of Protein Kinase A: Implications for Multiple Sclerosis. J Neurosci. 2017;37(41):9925-9938.
[14] RAWJI KS, GONZALEZ MARTINEZ GA, SHARMA A, et al. The Role of Astrocytes in Remyelination. Trends Neurosci. 2020;43(8):596-607.
[15] HUANG F, CHEN T, CHANG J, et al. A conductive dual-network hydrogel composed of oxidized dextran and hyaluronic-hydrazide as BDNF delivery systems for potential spinal cord injury repair. Int J Biol Macromol. 2021;167:434-445.
[16] AHI ZB, ASSUNCAO-SILVA RC, SALGADO AJ, et al. A combinatorial approach for spinal cord injury repair using multifunctional collagen-based matrices: development, characterization and impact on cell adhesion and axonal growth. Biomed Mater. 2020;15(5):55024.
[17] 卢仁培,邹志晨,赵丰年,等.聚乳酸-羟基乙酸共聚物复合支架在骨缺损修复再生中的作用与应用[J].中国组织工程研究,2022, 26(28):4525-4531.
[18] YU S, YAO S, WEN Y, et al. Angiogenic microspheres promote neural regeneration and motor function recovery after spinal cord injury in rats. Sci Rep. 2016;6:33428.
[19] JU R, WEN Y, GOU R, et al. The Experimental Therapy on Brain Ischemia by Improvement of Local Angiogenesis with Tissue Engineering in the Mouse. Cell Transplant. 2014;23(1_suppl):83-95.
[20] WEN Y, YU S, WU Y, et al. Spinal cord injury repair by implantation of structured hyaluronic acid scaffold with PLGA microspheres in the rat. Cell Tissue Res. 2016;364(1):17-28.
[21] HAN Q, ORDAZ JD, LIU N, et al. Descending motor circuitry required for NT-3 mediated locomotor recovery after spinal cord injury in mice. Nat Commun. 2019;10(1):5815.
[22] BASSO DM, BEATTIE MS, BRESNAHAN JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma. 1995;12(1):1-21.
[23] 董瑞,毕燕琳,王明山.旷场实验在鼠行为学研究中的应用[J].国际麻醉学与复苏杂志,2020,41(5):535-540.
[24] WANG J, LI D, LIANG C, et al. Scar Tissue‐Targeting Polymer Micelle for Spinal Cord Injury Treatment. Small. 2020;16(8):1906415.
[25] BADHIWALA JH, WILSON JR, FEHLINGS MG. Global burden of traumatic brain and spinal cord injury. Lancet Neurol. 2019;18(1):24-25.
[26] ZOU Y, MA D, SHEN H, et al. Aligned collagen scaffold combination with human spinal cord-derived neural stem cells to improve spinal cord injury repair. Biomater Sci. 2020;8(18):5145-5156.
[27] MARQUARDT LM, DOULAMES VM, WANG AT, et al. Designer, injectable gels to prevent transplanted Schwann cell loss during spinal cord injury therapy. Sci Adv. 2020;6(14):z1039.
[28] LIU D, SHEN H, SHEN Y, et al. Dual‐Cues Laden Scaffold Facilitates Neurovascular Regeneration and Motor Functional Recovery After Complete Spinal Cord Injury. Adv Healthc Mater. 2021;10(10):2100089.
[29] KWIECIEN J. Barriers to axonal regeneration after spinal cord injury: a current perspective. Neural Regen Res. 2022;17(1):85-86.
[30] LI G, ZHANG B, SUN JH, et al. An NT-3-releasing bioscaffold supports the formation of TrkC-modified neural stem cell-derived neural network tissue with efficacy in repairing spinal cord injury. Bioact Mater. 2021; 6(11):3766-3781.
[31] SMITH DR, DUMONT CM, PARK J, et al. Polycistronic Delivery of IL-10 and NT-3 Promotes Oligodendrocyte Myelination and Functional Recovery in a Mouse Spinal Cord Injury Model. Tissue Eng Part A. 2020; 26(11-12):672-682.
[32] SONG YH, AGRAWAL NK, GRIFFIN JM, et al. Recent advances in nanotherapeutic strategies for spinal cord injury repair. Adv Drug Deliv Rev. 2019;148:38-59.
[33] ZERAATPISHEH Z, MIRZAEI E, NAMI M, et al. Local delivery of fingolimod through PLGA nanoparticles and PuraMatrix-embedded neural precursor cells promote motor function recovery and tissue repair in spinal cord injury. Eur J Neurosci. 2021;54(4):5620-5637.
[34] SANTHOSH KT, ALIZADEH A, KARIMI-ABDOLREZAEE S. Design and optimization of PLGA microparticles for controlled and local delivery of Neuregulin-1 in traumatic spinal cord injury. J Control Release. 2017; 261:147-162.
[35] LOWRY N, GODERIE SK, LEDERMAN P, et al. The effect of long-term release of Shh from implanted biodegradable microspheres on recovery from spinal cord injury in mice. Biomaterials. 2011;33(10):2892-2901.
[36] ZERAATPISHEH Z, MIRZAEI E, NAMI M, et al. Local delivery of fingolimod through PLGA nanoparticles and PuraMatrix-embedded neural precursor cells promote motor function recovery and tissue repair in spinal cord injury. Eur J Neurosci. 2021;54(4):5620-5637.
[37] CONG Y, WANG C, WANG J, et al. NT-3 Promotes Oligodendrocyte Proliferation and Nerve Function Recovery After Spinal Cord Injury by Inhibiting Autophagy Pathway. J Surg Res. 2020;247:128-135.
[38] WANG Y, WU W, WU X, et al. Remodeling of lumbar motor circuitry remote to a thoracic spinal cord injury promotes locomotor recovery. Elife. 2018;7:e39016.
[39] GALLEGUILLOS D, WANG Q, STEINBERG N, et al. Anti-inflammatory role of GM1 and other gangliosides on microglia. J Neuroinflammation. 2022;19(1):9.
[40] LIN Y, LI C, LI J, et al. NEP1-40-modified human serum albumin nanoparticles enhance the therapeutic effect of methylprednisolone against spinal cord injury. J Nanobiotechnol. 2019;17(1):12.
[41] DE MIRANDA AS, DE BARROS J, TEIXEIRA AL. Is neurotrophin-3 (NT-3): a potential therapeutic target for depression and anxiety? Expert Opin Ther Targets. 2020;24(12):1225-1238.
[42] YU Y, LI Z, MA F, et al. Neurotrophin‐3 stimulates stem Leydig cell proliferation during regeneration in rats. J Cell Mol Med. 2020;24(23): 13679-13689.
[43] ELLIOTT DI, TATOR CH, SHOICHET MS. Local Delivery of Neurotrophin-3 and Anti-NogoA Promotes Repair After Spinal Cord Injury. Tissue Eng Part A. 2016;22(9-10):733-741.
[44] MORADIAN H, KESHVARI H, FASEHEE H, et al. Combining NT3-overexpressing MSCs and PLGA microcarriers for brain tissue engineering: A potential tool for treatment of Parkinson’s disease. Mater Sci Eng C Mater Biol Appl. 2017;76:934-943.
[45] MAGISTRETTI PJ, GEISLER FH, SCHNEIDER JS, et al. Gangliosides: Treatment Avenues in Neurodegenerative Disease. Front Neurol. 2019; 10:859.